– USA, CA – Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on commercializing novel vaccines, today announced Andrew A. F. Hack, M.D., Ph.D., a Managing Director at Bain Capital Life Sciences, has been appointed to Dynavax’s Board of Directors. The appointment follows an investment by Bain Capital Life Sciences in Dynavax’s recently completed public offering.
“We are pleased to welcome Andrew to our Board of Directors at this important time in Dynavax’s development as a commercial-stage vaccine company,” said Arnold L. Oronsky, Ph.D., Chairman of the Board of Directors of Dynavax. “As a highly respected and proven leader with extensive capital markets and biotechnology industry experience, Andrew is a strong strategic addition to our team. I’m confident that his valuable expertise will contribute significantly to Dynavax’s transformation.”
About Dr Andrew Hack
Dr. Hack is a Managing Director at Bain Capital Life Sciences, a private equity fund that invests in biopharmaceutical, specialty pharmaceutical, medical device, diagnostics, and enabling life science technology companies globally. Dr. Hack served as Chief Financial Officer of Editas Medicine, Inc. (NASDAQ: EDIT), from July 2015 to March 2019. Prior to joining Editas, he was a portfolio manager at Millennium Management LLC, an institutional asset manager, where he ran a healthcare fund focused on biotechnology, pharmaceutical, and medical device companies. Before joining Millennium, Dr. Hack was a healthcare analyst at HealthCor Management, L.P., a registered investment advisor. Previously, he served as a healthcare analyst for hedge fund Carlyle-Blue Wave Partners and as principal of the MPM BioEquities Fund, a hedge fund that was affiliated with MPM Capital. Earlier in his career, Dr. Hack was Director of Life Sciences and co-founder of Reify Corporation, a life science tools and drug discovery company. Dr. Hack serves as a director of Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) and Mersana Therapeutics, Inc. (NASDAQ: MRSN).
“It’s a privilege to join the Board and to help build Dynavax into a leading vaccine company,” said Dr. Hack. “HEPLISAV-B is well-positioned to become the market leader and the standard of care for adult hepatitis B vaccination and I look forward to partnering with the Board and Management to help ensure Dynavax’s success at this critical time in the Company’s evolution.”
He received his B.A. in biology with special honors from the University of Chicago, where he also received his M.D. and Ph.D.
Dynavax is a biopharmaceutical company focused on leveraging the power of the body’s innate and adaptive immune responses through toll-like receptor stimulation. Dynavax discovers, develops and commercializes novel vaccines. The Company launched its first commercial product, HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted], on February 2018, following U.S. FDA approval for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.
For more information: http://www.dynavax.com
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.